### Ranitidine

**Indication**
- Peptic ulcer, site unspecified

**INN**
- Ranitidine

**Medicine type**
- Chemical agent

**List type**
- Core

**Formulations**
- Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)

**EML status history**
- First added in 2003 (TRS 920)
- Changed in 2007 (TRS 950)
- Changed in 2021

**Sex**
- All

**Age**
- Also recommended for children

**Therapeutic alternatives**
- Medicines within the same pharmacological class can be used

**Therapeutic alternatives limitations**
- Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations)

**Therapeutic alternatives limitations for EMLc**
- Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations)

**Patent information**
- Patents have expired in most jurisdictions
  - Read more about patents.

**Wikipedia**
- [Ranitidine](https://en.wikipedia.org/wiki/Ranitidine)

**DrugBank**
- [Ranitidine](https://www.drugbank.ca/drugs/DB00675)

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that medicines in 4th level ATC chemical subgroup, A02BA H2-receptor antagonists (excluding combinations), be specified as therapeutic alternatives under the square box listing for ranitidine on the EML and EMLc.